Codis, a global contract development and manufacturing organisation (CDMO) specialising in spray drying, amorphous solid dispersions (ASDs) and advanced particle engineering, announces a key milestone in the ongoing PSD-4 expansion at the company’s site in Haverhill, UK.
The demolition of the existing redundant facilities is now complete, and makes space for the construction of the new building.
The construction milestone marks the next stage of Codis’ investment in a GEA Pharma-SD type PSD-4 solvent-capable spray dryer.
Following installation and validation, the PSD-4 will expand Codis’ commercial-scale solvent-based spray-drying capacity for ASDs, enabling pharmaceutical customers to advance poorly soluble drug candidates into larger-scale manufacturing.
Together with the company’s formulation development, analytical, clinical supply and oral solid dose capabilities in Nottingham, the investment will further connect development and manufacturing capabilities across Codis’ UK network, supporting programmes as they progress from early formulation through to commercial-scale spray drying.
“Completing demolition and moving into construction is an important milestone for the PSD-4 expansion," commented Nick Hodgson, Vice President & General Manager, Haverhill Operations.
"By building within our existing Haverhill facility and utilising established site infrastructure, we can deliver the additional capacity efficiently while building on the expertise and capabilities already in place in our 100,000 sqft cGMP facility.”
The PSD-4 expansion remains on schedule, with the next key milestone, the Dryer Factory Acceptance Test (FAT), due to take place in November.
The new spray drying capacity is expected to become available in the last quarter of 2027.
